Study S001002

The Effects of Short-Term Exenatide Therapy on the Beta-Cell Function and Long-term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01270191
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: UNKNOWN
Enrollment: 160
Start: 2010-11
Primary completion: 2014-12
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Conditions: Type 2 Diabetes
Interventions: DRUG:Exenatide; DRUG:Humulin-N
Results posted: FALSE

Registered primary outcomes

the time of glycemic remission and remission rate [at one year]
The time of monotherapy failure and monotherapy failure rate [5 years]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012661	Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia. Wu TH, Journal of the Chinese Medical Association : JCMA	2026	Randomized trial	PMID 42290292 DOI	cites ClinicalTrials.gov:NCT01270191; registry reference DERIVED:42290292